This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Oct 30;376(9751):1441-2.

doi: 10.1016/S0140-6736(10)61497-3. Epub 2010 Oct 14.

Curing hepatitis C with pills: a step toward global control

David L Thomas¹

Affiliations

PMID: 20951421
PMCID: PMC4083467
DOI: 10.1016/S0140-6736(10)61497-3

Comment

Curing hepatitis C with pills: a step toward global control

David L Thomas. Lancet. 2010.

. 2010 Oct 30;376(9751):1441-2.

doi: 10.1016/S0140-6736(10)61497-3. Epub 2010 Oct 14.

Author

David L Thomas¹

Affiliation

¹ Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. dthomas@jhmi.edu

PMID: 20951421
PMCID: PMC4083467
DOI: 10.1016/S0140-6736(10)61497-3

No abstract available

PubMed Disclaimer

Figures

Figure 1
Schematic representation of low global impact of improving HCV treatment efficacy without expanding HCV testing and treatment initiation. A=overall sustained virological response rates (SVR) possible with major developments in HCV treatment and projections of 90% SVR with new drugs. B=population impact calculated by multiplying efficacy figures from A by estimate of percent of individuals worldwide who have started HCV treatment. 2001 shown because pegylated interferon alfa and ribavirin were first approved then (peginterferon alfa 2a approved in 2002), the latest upgrade in HCV treatment

See this image and copyright information in PMC

Comment on

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Gane EJ, et al. Lancet. 2010 Oct 30;376(9751):1467-75. doi: 10.1016/S0140-6736(10)61384-0. Epub 2010 Oct 14. Lancet. 2010. PMID: 20951424 Clinical Trial.

Similar articles

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Gane EJ, et al. Lancet. 2010 Oct 30;376(9751):1467-75. doi: 10.1016/S0140-6736(10)61384-0. Epub 2010 Oct 14. Lancet. 2010. PMID: 20951424 Clinical Trial.
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, Smith P, Bradford W, Porter S, Blatt L, Seiwert SD, Zeuzem S. Forestier N, et al. J Hepatol. 2011 Jun;54(6):1130-6. doi: 10.1016/j.jhep.2010.11.001. Epub 2011 Feb 24. J Hepatol. 2011. PMID: 21145848 Clinical Trial.
Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.
Aghemo A, De Francesco R. Aghemo A, et al. Gut. 2015 Jun;64(6):860-2. doi: 10.1136/gutjnl-2014-307958. Epub 2014 Sep 5. Gut. 2015. PMID: 25193803 No abstract available.
[Future antiviral therapy for chronic hepatitis C].
Tanaka K. Tanaka K. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):528-33. Nihon Rinsho. 2004. PMID: 15359856 Review. Japanese. No abstract available.
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
Höner zu Siederdissen C, Cornberg M. Höner zu Siederdissen C, et al. Dtsch Med Wochenschr. 2014 Nov;139(47):2411-4. doi: 10.1055/s-0034-1387382. Epub 2014 Nov 12. Dtsch Med Wochenschr. 2014. PMID: 25390631 Review. German. No abstract available.

See all similar articles

Cited by

Pursuing Elimination of Hepatitis C in Egypt: Cost-Effectiveness and Economic Evaluation of a Country-Wide Program.
Schwander B, Feldstein J, Sulo S, Gonzalez L, ElShishiney G, Hassany M. Schwander B, et al. Infect Dis Ther. 2022 Jun;11(3):1193-1203. doi: 10.1007/s40121-022-00631-x. Epub 2022 Apr 22. Infect Dis Ther. 2022. PMID: 35451742 Free PMC article.
Effect of Sofosbuvir Administration and Its Withdrawal on the Submandibular Salivary Gland of Adult Male Albino Rats: A Histological and Ultra-Structural Study.
Abdeen AM, Essawy T, Mohammed SS. Abdeen AM, et al. Open Access Maced J Med Sci. 2019 Dec 10;7(23):4101-4109. doi: 10.3889/oamjms.2019.868. eCollection 2019 Dec 15. Open Access Maced J Med Sci. 2019. PMID: 32165960 Free PMC article.
Epidemiology and management of hepatitis C virus infections in immigrant populations.
Coppola N, Alessio L, Onorato L, Sagnelli C, Macera M, Sagnelli E, Pisaturo M. Coppola N, et al. Infect Dis Poverty. 2019 Mar 15;8(1):17. doi: 10.1186/s40249-019-0528-6. Infect Dis Poverty. 2019. PMID: 30871599 Free PMC article. Review.
Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.
Mölleken C, Ahrens M, Schlosser A, Dietz J, Eisenacher M, Meyer HE, Schmiegel W, Holmskov U, Sarrazin C, Sorensen GL, Sitek B, Bracht T. Mölleken C, et al. Clin Mol Hepatol. 2019 Mar;25(1):42-51. doi: 10.3350/cmh.2018.0029. Epub 2018 Nov 19. Clin Mol Hepatol. 2019. PMID: 30449076 Free PMC article.
Epidemiology and Elimination of HCV-Related Liver Disease.
Pradat P, Virlogeux V, Trépo E. Pradat P, et al. Viruses. 2018 Oct 6;10(10):545. doi: 10.3390/v10100545. Viruses. 2018. PMID: 30301201 Free PMC article. Review.

See all "Cited by" articles

References

1. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–1838. - PubMed
1. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376:705–716. - PubMed
1. Gane, et al. Lancet
1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982. - PubMed
1. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580–593. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

R01 DA013324/DA/NIDA NIH HHS/United States

LinkOut - more resources

Full Text Sources